Bitcoin briefly fell below $81,000 following a sell-off in U.S. tech stocks and Asian equities, with Nasdaq dropping 2.6% and semiconductor stocks plunging. Despite this, experts note Bitcoin's resilience compared to tech stocks, highlighting its strong network security and institutional backing. Gold and silver also declined, while Brent crude rose due to Middle East tensions. Analysts view the current market as an early bull opportunity rather than a warning of a downturn.
Bitcoin market moves provide context for readers. As of Oct 24, 2026 02:31 WIB, 36 of 50 major cryptocurrencies on Pluang rose, 13 fell. Notable movers include ATOM at Rp31.613 (+2.92%), YFI at Rp39.776.295 (+2.84%), and LUNC at Rp0,832 (+2.50%).
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
